Breast Cancer Chemoprevention: A Review of Selective Estrogen Receptor Modulators

Ann M. Johansen

CJON 2005, 9(3), 317-320. DOI: 10.1188/05.CJON.317-320

Breast cancer is the most common cancer diagnosis among women in the United States. Chemoprevention plays an important role for women at high risk for developing breast cancer. The use of selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene has demonstrated mixed results in breast cancer prevention clinical trials. In the United States, tamoxifen is approved for use for breast cancer prevention in women at high risk. The continued development of SERMs with improved side-effect profi les is needed. Oncology nurses play a pivotal role in helping patients to understand the current status of breast cancer prevention as well as the future direction of research.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.